• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biodesix, Inc. - Common Stock (NQ:BDSX)

    26.83 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 26.83
    Bid (Size) 23.00 (200)
    Ask (Size) 29.95 (600)
    Prev. Close 26.83
    Today's Range 26.83 - 26.83
    52wk Range 5.260 - 31.31
    Shares Outstanding 78,614,114
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Biodesix (BDSX) Q2 2026 Earnings Call Transcript ↗
    Revenue jumped 34% as diagnostic testing surged on primary care adoption gains. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference ↗
    Biodesix (NASDAQ:BDSX) said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the... 
    Via MarketBeat

    Performance

    YTD
    +315.3%
    +315.3%
    1 Month
    +26.6%
    +26.6%
    3 Month
    +75.7%
    +75.7%
    6 Month
    +70.3%
    +70.3%
    1 Year
    +209.4%
    +209.4%

    More News

    Read More
    News headline image
    Biodesix Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Biodesix (NASDAQ:BDSX) Q2 EPS Beats, Revenue In Line, Shares Slip ↗
    Via Chartmill
    Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance ↗
    Via Chartmill
    Biodesix Inc (NASDAQ:BDSX) Reports Q4 2025 Earnings Beat and First Adjusted EBITDA Profitability ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Biodesix Announces Second Quarter 2026 Results and Highlights
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Participate in Upcoming Investor Conferences
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix (BDSX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Biodesix BDSX Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Biodesix Announces First Quarter 2026 Results and Highlights
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix Recognized as a Top Workplace for Third Consecutive Year
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix (BDSX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Participate in Upcoming Investor Conferences
    From Biodesix, Inc.
    Via GlobeNewswire
    News headline image
    Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
    From Biodesix, Inc.
    Via GlobeNewswire
    Which stocks are moving on Wednesday? ↗
    Via Chartmill
    Curious about the stocks that are showing activity after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
    Via MarketMinute
    Topics Artificial Intelligence Death

    Frequently Asked Questions

    Is Biodesix, Inc. - Common Stock publicly traded?
    Yes, Biodesix, Inc. - Common Stock is publicly traded.
    What exchange does Biodesix, Inc. - Common Stock trade on?
    Biodesix, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Biodesix, Inc. - Common Stock?
    The ticker symbol for Biodesix, Inc. - Common Stock is BDSX on the Nasdaq Stock Market
    What is the current price of Biodesix, Inc. - Common Stock?
    The current price of Biodesix, Inc. - Common Stock is 26.83
    When was Biodesix, Inc. - Common Stock last traded?
    The last trade of Biodesix, Inc. - Common Stock was at 08/28/26 04:00 PM ET
    What is the market capitalization of Biodesix, Inc. - Common Stock?
    The market capitalization of Biodesix, Inc. - Common Stock is 2.11B
    How many shares of Biodesix, Inc. - Common Stock are outstanding?
    Biodesix, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.